Zobrazeno 1 - 10
of 2 443
pro vyhledávání: ''
Publikováno v:
General Thoracic and Cardiovascular Surgery. 70:96-99
A 71-year-old female with type B3 thymoma developed severe aplastic anemia. Anti-thymocyte globulin was administered with glucocorticoids and cyclosporin A as the treatment for aplastic anemia. Computed tomography scan revealed that thymoma apparentl
Publikováno v:
Journal of Cardiovascular Pharmacology. 78:202-210
This review aimed to summarize the adverse events (AEs) reported during the use of sacubitril/valsartan versus angiotensin converting enzyme inhibitors (ACEI)/angiotensin II receptor blocker (ARB). Studies containing safety outcomes or AEs during the
Autor:
Byung Woo Jhun, Nam Yong Lee, Noeul Kang, Kyeongman Jeon, O Jung Kwon, Won-Jung Koh, Hee Jae Huh, Charles L. Daley, Hojoong Kim
Publikováno v:
Chest. 160:436-445
Mycobacterium abscessus pulmonary disease (M abscessus-PD) is challenging to treat because of its resistance to antibiotics.What are the outcomes of treatment-naive patients with M abscessus-PD treated with inhaled amikacin-containing multidrug regim
Autor:
Mary E. Keebler, Moses Demehin, Christopher M. Sciortino, Massimo Mangiola, Ed Horn, Roy Sriwattanakomen, Qingyong Xu, Adriana Zeevi, M. Shullo, Gavin Hickey
Publikováno v:
The Journal of Heart and Lung Transplantation. 40:595-603
Background Allosensitization in heart transplant candidates is associated with longer transplant wait times and post-transplant complications. We summarize our experience with desensitization using carfilzomib , an irreversible proteasome inhibitor t
Autor:
Ran Tian, Haiping Xing, Yiyang Wang, Haopeng Xu, Lifeng Liang, Siqin Feng, Shuyang Zhang, Honghong Liu, Yifei Wang, Hui Wang
Publikováno v:
Nutrition, Metabolism and Cardiovascular Diseases. 31:1454-1466
Background and aims Host–microbiota interactions involving metabolic pathways have been linked to the pathogenesis of atherosclerotic disease and type 2 diabetes. As stable coronary artery disease (SCAD) patients combined with type 2 diabetes have
Publikováno v:
Nutrition, Metabolism and Cardiovascular Diseases. 31:1276-1285
Background and aims Dual antiplatelet therapy (DAPT) and Renin-angiotensin system inhibitors (RASi) represent the cornerstone in the treatment of patients undergoing percutaneous coronary interventions (PCI), mainly after an acute ischemic event. How
Autor:
Rosa Diaz Campillejo, Guillermo Gervasini, J. Villa, Nicolás Roberto Robles, Elena Garcia de Vinuesa, Julian Valladares
Publikováno v:
Cardiovascular & Hematological Agents in Medicinal Chemistry. 19:93-97
Background and Aims: Anemia is a common complication of heart failure and Chronic Kidney Disease (CKD). Sacubitril-valsartan is a novel therapy for the treatment of chronic Heart Failure with a reduced Ejection Fraction (HFrEF). We have evaluated the
Autor:
Michal Dubský, Robert Bém, Vladimíra Fejfarová, Karol Sutoris, Alexandra Jirkovská, Edward B. Jude, Jitka Husáková, Jelena Skibova, Andrea Nemcova
Publikováno v:
Angiology. 72:861-866
Autologous cell therapy (ACT) is a new treatment for patients with no-option critical limb ischemia (NO-CLI). We evaluated the factors involved in the nonresponse to ACT in patients with CLI and diabetic foot. Diabetic patients (n = 72) with NO-CLI t
Autor:
Areti Pagiantza, Ioannis Farmakis, Stefanos Zafeiropoulos, Ioannis Doundoulakis, Haralambos Karvounis, George Giannakoulas, Christina Antza
Publikováno v:
Journal of Cardiovascular Pharmacology. 77:397-407
Lipoprotein(a) [Lp(a)] is a cardiovascular factor, for which there is no approved specific lowering treatment. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to have lowering effects on Lp(a). Aim of this systematic
Publikováno v:
Cardiovasc Res
Ageing is the most significant contributor to the increasing prevalence of atrial fibrillation (AF). The gut microbiota dysbiosis is involved in age-related diseases. However, whether the aged-associated dysbiosis contributes to age-related AF is sti